Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Bavarian Nordic A/S (OTC: BVNRY).

Full DD Report for BVNRY

You must become a subscriber to view this report.


Recent News from (OTC: BVNRY)

Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine
Broad antibody and T cell responses against RSV remained durable 1 year post a single vaccination with MVA-BN® RSV in the majority of subjects An annual booster of MVA-BN-RSV induced a broad and robust immune response, particularly in subjects with waning immunity one year after f...
Source: GlobeNewswire
Date: August, 08 2018 08:08
Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer
Investigator-led study has commenced dosing Immunotherapy candidate CV301 is being assessed in combination with checkpoint inhibitors in multiple solid tumors COPENHAGEN, Denmark, July 11, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the first patient has b...
Source: GlobeNewswire
Date: July, 11 2018 06:01
Bavarian Nordic (BVNRY) Presents At Citi 2018 European Healthcare Conference - Slideshow
The following slide deck was published by Bavarian Nordic A/S ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: June, 19 2018 14:07
Pfizer launches RSV vaccine study
Pfizer ( PFE +0.4% ) commences a Phase 1/2 clinical trial assessing its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. The primary endpoints are safety and tolerability. The secondary endpoint is immunogenicity. More news on: Pfizer Inc., Novavax, In...
Source: SeekingAlpha
Date: May, 22 2018 09:49
Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
COPENHAGEN, Denmark, May 16, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the acceptance of 4 poster presentations and one podium presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1-5, 2018 in Chicago Illinois. These abstracts ...
Source: GlobeNewswire
Date: May, 16 2018 17:00
Bavarian Nordic inks deal with U.S. DoD for equine encephalitis virus vaccine; shares up 3%
Bavarian Nordic A/S ( OTCPK:BVNRY +3.3% ) has secured $36M multiyear contract from the U.S. Department of Defense (DoD) to support the development of a prophylactic vaccine against the mosquito-borne equine encephalitis virus. More news on: Bavarian Nordic A/S ADR, Healthcare stocks ne...
Source: SeekingAlpha
Date: March, 16 2018 09:52
Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus
Collaboration valued up to $36M Multivalent vaccine designed to protect humans against Eastern, Venezuelan, and Western equine encephalitis virus COPENHAGEN, Denmark, March 16, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the signing of a new alliance with t...
Source: GlobeNewswire
Date: March, 16 2018 08:54
Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
Bavarian Nordic and Bristol-Myers Squibb agree to supply clinical material for the trial Investigator-led study represents the fourth clinical combination of CV301 with a checkpoint inhibitor COPENHAGEN, Denmark, March 8, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today a...
Source: GlobeNewswire
Date: March, 08 2018 08:59
Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine
Presence of antibodies in nasal mucosa suggest vaccine-induced immune protection at source of infection IgA antibodies against RSV observed in both serum and mucosa of vaccinated individuals COPENHAGEN, Denmark, March  6, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) t...
Source: GlobeNewswire
Date: March, 06 2018 08:33
Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers
Third evaluation of CV301 in combination with a checkpoint inhibitor Multicenter investigator-sponsored trial to be led by Georgetown University COPENHAGEN, Denmark, February 26, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced a new collaboration that will inve...
Source: GlobeNewswire
Date: February, 26 2018 04:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-10N/A6.99N/AN/A0
2018-12-07N/A6.99N/AN/A0
2018-12-06N/A6.99N/AN/A0
2018-12-056.996.996.996.99100
2018-12-046.996.996.996.99100

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-09-2036946978.6780Short
2018-09-11900900100.0000Short
2018-07-20400400100.0000Short
2018-06-27143513.9886Cover
2018-06-218001,00579.6020Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BVNRY.


About Bavarian Nordic A/S (OTC: BVNRY)

Logo for Bavarian Nordic A/S (OTC: BVNRY)

Not available

 

 

 

Current Share Structure

     



    Daily Technical Chart for (OTC: BVNRY)

    Daily Technical Chart for (OTC: BVNRY)


    Stay tuned for daily updates and more on (OTC: BVNRY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: BVNRY)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BVNRY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BVNRY and does not buy, sell, or trade any shares of BVNRY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/